Research and Development themes and projects
for Drug Discovery and Medical Technology
The Drug Discovery and Medical Technology platforms aim to deliver innovative drugs andmedical technologies to patients with unmet medical needs and/or possessing rare disease
currently, we are conducting research and development with the highest priority given to theorder of the themes and projects shown in the table below.
⚫

The stages are divided into three components, S (seed) stage, L (lead) stage, and P (clinical)
stage, where each stage is further subdivided into S0 to S3, L1 to– L3, and P0 to P3.

⚫

Project (L3 to P3): Advance candidate compounds, antibodies, or technology to non-clinicaland clinical development under the direction of a project leader.

⚫

Theme (S0 to L2): Promote selection of drug candidates or antibodies, and develop orimprove technology in cooperation with theme leaders and portfolio managers.

⚫

The abbreviations for modality are:
AB: Antibody; BT: Basic Technology; CT/RM: Cell Therapy or Regenerative Medicine; MD:
Medical Device; NA: Nucleic Acid; SM: Small Molecule.

Oncology area
Theme/Project
Artificial adjuvant vector cells I(WT1)
Cancer treatment by iPS NKT Cell

Theme/ProjectLeader

Project

KOSEKI Haruhiko

CT/RM

ProjectSMProject

FUJII Shin-ichiro

CT/RMProject

ITO Akihiro

SMThemeMORI Kazutoshi

SM

ThemeSM

Theme

SM

Themeinhibitors

HiroyukiAnti-cancer drugs targeting
SIRT2

Theme (S0 to L2)

CT/RM

SEIMIYA(HPV)

Project (L3 to P3)/

FUJII Shin-ichiro

Development of tankyrase

Artificial adjuvant vector cells II

Modality

Unfolded protein response for thedevelopment of new anti-cancerdrugs
Development of anti-cancer drug
targeting histone
acetyltransferase
Diagnostic and therapeutic
molecules on the basis of acrolein
as cancer biomarker

YUSA Kosuke
HARADA Hironori
TANAKA
Katsunori

Cell recognition platform byTANAKA

glycan patterns

Katsunori

BT

Theme

Infectious disease area
Theme/Project
Artificial adjuvant vector cells III(SARS-CoV-2)
Antifungal drug
Antibody drug development toprevent SARS-CoV-2 infection

Theme/Project
LeaderModality

Project (L3 to P3)/
Theme (S0 to L2)

FUJII Shin-ichiro

CT/RM

Project

YOSHIDA Minoru

SMTheme

SAITO Takashi

ABTheme

Psychiatric / neurological disease area
Theme/Project

Theme/Project
LeaderModality

Project (L3 to P3)/
Theme (S0 to L2)Development of novel therapeutic
agents for mood disorders
targeting mitochondrial
permeability transition pore

KUBOTA-SM

Theme

ASO Teijiro

SMTheme

ITO Takuhiro

SMThemeSM

ThemeNATheme

AB

Theme

AB

Theme

SAKASHITA Mie(mPTP)
Development of drug for
Alzheimer's disease targeting anew mechanism
Development of integrated stressresponse inhibitors
Pathophysiologicalinvestigations and developmentof molecularly targeted drugs for
cerebral aneurysms based on

NAKATOMI
Hirofumi

genetic mutations
Development of drug for repeat
diseases

INOUE Haruhisa

Development of diagnostic agents

TANAKAfor repeat disease

Motomasa

Development of antibody therapy

TANAKA

for Alzheimer’s disease

MotomasaDevelopment of GPCR-targeted
therapeutics forneurodegenerative diseases

KAMIGUCHI
Hiroyuki

SM

Theme

Congenital disease area
Theme/Project

Theme/Project
LeaderModality

Project (L3 to P3)/
Theme (S0 to L2)Development of G9a inhibitors fortreatment of hemoglobinopathy

ITO Akihiro

SM

Project

SM

Theme

SM

Theme

SM

Theme

SM

Theme

SUZUKI Tadashi

SM

Theme

HAYASHI Yohei

SM

Theme(SCD）
Development of a drug for Fabry
disease targeting a suppression

KOBAYASHIof globotriaosylceramide (Gb3)

Hirokiaccumulation
Drug for congenital aplastic
anemia

HIROYAMA
TakashiDrug for Diamond-Blackfan
anemia

HIROYAMA
Takashi

Development of drugs for
improving mitochondrial
respiratory function

KOBAYASHI
HirokiDiscovery of FBS2 inhibitors as
novel therapeutics for NGLY1
deficiency
Development of anti-cancer
drugs using iPS cells derived from
VHL patients
Gastrointestinal disease area
Theme/Project
Antibody drug for hepatitis B
Drug development for hepatitis B

Theme/Project
Leader
CHAYAMA
Kazuaki
OGAWA Kenji

Modality

Project (L3 to P3)/
Theme (S0 to L2)

ABThemeSMThemeImmune / allergic disease area
Theme/Project
Drug for atopic dermatitis

Theme/Project
LeaderMIYAI Tomohiro

ModalitySM

Project (L3 to P3)/
Theme (S0 to L2)
Theme

Other area
Theme/Project
Establishment of a heart-on-achip microdevice based onhuman iPS Cells

Theme/Project
Leader
MASUMOTO
Hidetoshi

Modality

Project (L3 to P3)/
Theme (S0 to L2)

BT

Theme

SM

Theme

Mitochondrial translationmonitoring drug screening

IWASAKI

platform for mitochondrial

Shintarodiseases